<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1030">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147740</url>
  </required_header>
  <id_info>
    <org_study_id>CO-US-38-5713</org_study_id>
    <nct_id>NCT05147740</nct_id>
  </id_info>
  <brief_title>Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age</brief_title>
  <official_title>Switching to a Fixed Dose Combination of Biktarvy in Treatment Experienced People With HIV Who Are Currently Virologically Suppressed and at Least 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulika Singh, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Desert AIDS Project</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess patient reported treatment satisfaction and medication tolerability in&#xD;
      virologically suppressed HIV-1 infected adults who are at least 65 years of age who switch to&#xD;
      a bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in treatment satisfaction by a change in total satisfaction scale as measured by the HIVTSQ survey.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Improvement in treatment satisfaction by a change in total satisfaction scale as measured by the HIVTSQ survey. The range of scores is between -33 and +33. The higher the score, the greater the improvement in satisfaction. Satisfaction may be positive or negative.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in overall quality of life as characterized by a change in total satisfaction scale as measured by the HIVDQoL survey.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Improvement in overall quality of life as characterized by a change in total satisfaction scale as measured by the HIVDQoL survey. The range of scores is between -9 to +3. The higher the score the greater the impact. Impacts may be positive or negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of all participants who have plasma HIV-1 RNA Viral Load &lt; 50 c/mL at W24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of all participants who have plasma HIV-1 RNA Viral Load &lt; 50 c/mL at W24 using FDA snapshot analysis, which defined a participant's virologic response status using only the viral load at the predefined timepoint within a certain window of time, along with study drug discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of all participants who have plasma HIV-1 RNA Viral Load &lt; 50 c/mL at end of study</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of all participants who have plasma HIV-1 RNA Viral Load &lt; 50 c/mL at end of study (Week 48) using FDA snapshot analysis, which defined a participant's virologic response status using only the viral load at the predefined timepoint within a certain window of time, along with study drug discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants experiencing Adverse Events (AEs) through End of Study (Week 48)</measure>
    <time_frame>Week 48</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related . An AE can be any unfavorable and unintended sign, symptom, or disease associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who reduced their number of total medications from baseline.</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of patients who reduced their number of total medications from baseline. Polypharmacy is defined as 5 or more prescription medications and the Beers Criteria is utilized as a tool to evaluate potentially inappropriate prescriptions in this population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B/F/TAF for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>50/200/25 mg fixed-dose combination administered orally once daily without regard to food.</description>
    <arm_group_label>B/F/TAF</arm_group_label>
    <other_name>Biktarvy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Be at least 65 years of age at the time of signing the informed consent form.&#xD;
&#xD;
          2. Be currently receiving an antiretroviral regimen for ≥ 3 months prior to the screening&#xD;
             visit.&#xD;
&#xD;
          3. Have documented plasma HIV-1 RNA &lt; 50 copies/mL for a minimum of 3 months on current&#xD;
             ART regimen.&#xD;
&#xD;
          4. Have a plasma HIV-1 RNA &lt; 50 copies/mL at screening visit.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Have resistance to tenofovir (K65R/E/N, ≥3 thymidine analogue mutations or&#xD;
             T69-insertions), primary INSTI-resistance, or a history of failure on an INSTI-based&#xD;
             regimen.&#xD;
&#xD;
          2. Have been treated with B/F/TAF&#xD;
&#xD;
          3. Participants with CrCl &lt;30 mL/min&#xD;
&#xD;
          4. Known or suspected severe hepatic impairment (Child-Pugh Class C)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tulika Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DAP Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greg Jackson, BS, MBA</last_name>
    <phone>760-992-0445</phone>
    <email>gjackson@daphealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>DAP Health</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Jackson, BS, MBA</last_name>
      <phone>760-992-0445</phone>
      <email>gjackson@daphealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Karina Ramirez</last_name>
      <phone>760-656-8450</phone>
      <email>kramirez@daphealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tulika Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Saavedra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Desert AIDS Project</investigator_affiliation>
    <investigator_full_name>Tulika Singh, MD</investigator_full_name>
    <investigator_title>Director of Research and Associate Chief Medical Officer</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>QOL</keyword>
  <keyword>Elderly</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

